Influence Of Early Treatment Research Articles

Early treatment of Class Ⅲ malocclusion based on craniomaxillofacial growth and development

More and more attention has been paid to the early treatment of malocclusion, especially the early treatment of class Ⅲ malocclusion. Class Ⅲ malocclusion not only affects maxillofacial growth and development, occlusal function and facial beauty, but also leads to serious physical and mental problems. Focusing on class Ⅲ malocclusion, the definition, classification, etiological mechanism, craniofacial growth and development rule, and the influence of early treatment on craniofacial growth and development were reviewed. In class Ⅲ patients, the craniofacial growth and development should be evaluated and analyzed when the early intervention carried out. The purpose of treatment of class Ⅲ malocclusion is achieved by using the appliance to affect the craniomaxillofacial growth.

Influence of early treatment of pregnancy combined with subclinical hypothyroidism on pregnancy outcome

Objective To analyze the influence of early treatment of pregnancy combined with subclinical hypothyroidism (SCH) during pregnancy on pregnancy outcome. Methods From January 2013 to June 2015, 128 pregnant women who were diagnosed as SCH in the Maternal and Child Health Hospital of Beilun District were randomly divided into the observation group and control group according to the digital table, with 64 cases in each group.The observation group was given levothyroxine early treatment, while the control group adopted conventional hospitalization, unexposed.Pregnancy outcomes of the two groups were analyzed. Results After treatment, the incidence rates of complications in the observation group: preeclampsia (4.69%), poor fetal growth (1.56%), premature rupture of membranes (7.81%), less amniotic fluid volume (4.69%), placental abruption (0%), postpartum hemorrhage (3.12%); the incidence rates of complications in the control group: preeclampsia (17.19%), poor fetal growth (10.94%), premature rupture of membranes (21.88%), less amniotic fluid volume (15.63%), placental abruption (6.25%), postpartum hemorrhage (12.50%), and there were statistically significant differences between two groups (χ2=5.133, 4.800, 5.006, 4.195, 4.129, 3.905, P=0.023, 0.028, 0.025, 0.041, 0.042.0.048). After treatment, the incidence rates of adverse pregnancy outcomes: preterm birth (3.12%), cesarean section(60.94%), abortion(0.00%), fetal distress(4.69%), perinatal death (0.00%); the incidence rates of adverse pregnancy outcomes in the control group: preterm birth(12.50%), cesarean section (79.69%), abortion (7.81%), fetal distress (15.63%), perinatal death (6.25%), and the differences between the two groups were statistically significant (χ2=3.905, 5.389, 5.203, 4.195, 4.129, P=0.048, 0.020, 0.023, 0.041, 0.042). Conclusion Pregnancy complicated with SCH has different degree influence on patients with obstetric complications and outcome of pregnancy, early effective drug treatment can significantly reduce the incidence of obstetric complications and adverse pregnancy outcomes. Key words: Pregnancy; Hypothyroidism, subclinical; L-thyroxine; Pregnancy outcome; Cesarean delivery; Prematue rupture of memmbranes

Clinical Implications for the Early Treatment of Benign Prostatic Enlargement (BPE): a Systematic Review.

Therapeutic options for the management of lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement (BPE) have considerably increased in recent years. However, the ideal timing to initiate medical treatment of LUTS/BPE has not been fully established. The aim of this review was to systematically collect available evidence on the influence of early treatment on the natural history of LUTS/BPE patients. A systematic literature search from January 1996 until April 2018 was performed by combining the following MESH terms: Lower Urinary Tract Symptoms, Benign Prostatic Enlargement, male, medical treatment, surgical treatment, early treatment/intervention, and early intervention/treatment. The Medline, PubMed, and Scopus databases were searched. Each article title and abstract was reviewed for relevance and appropriateness with regard to the topic of this review. In recent years, the medical armamentarium for the management of LUTS secondary to BPE has been extensively implemented, significantly improving treatment outcomes and markedly reducing the need for BPE surgery. Early intervention in patients at risk for disease progression may offer better clinical outcomes compared to a deferred approach. However, evidences supporting early treatment are scarce, and criteria to discriminate patients that could mostly benefit from immediate treatment remain poorly defined. Moreover, as a result of delayed surgery after prolonged medical treatment, patients undergoing surgical relief show larger prostates, older age, and comorbidities. Nevertheless, technological advancements in surgical techniques have largely counterweighed this critical scenario, and commonly, a non-pejorative trend has been reported in perioperative complications. The timeliest moment to start a medical treatment in LUTS/BPE patients is still undefined, and unexpectedly, peer-reviewed evidence remains scarce. Further studies are awaited to better discriminate patients who mostly benefit from early treatment of LUTS/BPE.

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions.

Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of progression to symptomatic multiple myeloma (MM) or amyloidosis. In comparison to monoclonal gammopathy of undetermined significance (MGUS), SMM has a much higher risk of progression to MM. Thanks to advances in our understanding of the risk factors, the subset of patients with ultra-high risk of progression to MM (80%–90% at 2 years) has been identified. The revision of the diagnostic criteria resulted in changes in the management of this cohort of patients. In contrast to the management guidelines for MGUS patients, SMM patients need to be studied more intensively in order to identify biomarkers necessary for accurate risk stratification. In this review, we focus on the risk of progression from SMM to MM, as well as the influence of early treatment on overall survival, time to progression and quality of life.

GW27-e1035 The effect of methylation of ATRAP gene on left ventricular hypertrophy in spontaneously hypertensive rats treated early with losartan

To investigate long-term influence of early treatment of spontaneously hypertensive rats (SHR) with losartan (Los) on blood pressure, left ventricular hypertrophy and expression of angiotensin type 1 receptor-associated protein (ATRAP) in myocardium, and to explore the role of DNA methylation in the

One-phase vs 2-phase treatment for developing Class III malocclusion: A comparison of identical twins

Despite the known influence of early treatment on the facial appearance of growing patients with skeletal Class III malocclusion, few comparative reports on the long-term effects of different treatment regimens (1-phase vs 2-phase treatment) have been published. Uncertainty remains regarding the effects of early intervention on jaw growth and its effectiveness and efficiency in the long term. In this case report, we compared the effects of early orthodontic intervention as the first phase of a 2-phase treatment vs 1-phase fixed appliance treatment in identical twins over a period of 11 years. Facial and dental changes were recorded, and cephalometric superimpositions were made at 4 time points. In spite of the different treatment approaches, both patients showed identical dentofacial characteristics in the retention phase. Through this case report, we intended to clarify the benefits of undergoing 1-phase treatment against 2-phase treatment protocols for treating growing skeletal Class III patients.